General Information of Drug Therapeutic Target (DTT) (ID: TTT2LD9)

DTT Name GABA transaminase (ABAT)
Synonyms L-AIBAT; Gamma-amino-N-butyrate transaminase; GABA-T; GABA-AT; GABA aminotransferase; ABAT; (S)-3-amino-2-methylpropionate transaminase
Gene Name ABAT
DTT Type
Successful target
[1]
BioChemical Class
Transaminase
UniProt ID
GABT_HUMAN
TTD ID
T59045
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.6.1.19
Sequence
MASMLLAQRLACSFQHSYRLLVPGSRHISQAAAKVDVEFDYDGPLMKTEVPGPRSQELMK
QLNIIQNAEAVHFFCNYEESRGNYLVDVDGNRMLDLYSQISSVPIGYSHPALLKLIQQPQ
NASMFVNRPALGILPPENFVEKLRQSLLSVAPKGMSQLITMACGSCSNENALKTIFMWYR
SKERGQRGFSQEELETCMINQAPGCPDYSILSFMGAFHGRTMGCLATTHSKAIHKIDIPS
FDWPIAPFPRLKYPLEEFVKENQQEEARCLEEVEDLIVKYRKKKKTVAGIIVEPIQSEGG
DNHASDDFFRKLRDIARKHGCAFLVDEVQTGGGCTGKFWAHEHWGLDDPADVMTFSKKMM
TGGFFHKEEFRPNAPYRIFNTWLGDPSKNLLLAEVINIIKREDLLNNAAHAGKALLTGLL
DLQARYPQFISRVRGRGTFCSFDTPDDSIRNKLILIARNKGVVLGGCGDKSIRFRPTLVF
RDHHAHLFLNIFSDILADFK
Function
Catalyzes the conversion of gamma-aminobutyrate and L- beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate andbeta-alanine.
KEGG Pathway
Alanine, aspartate and glutamate metabolism (hsa00250 )
Valine, leucine and isoleucine degradation (hsa00280 )
beta-Alanine metabolism (hsa00410 )
Propanoate metabolism (hsa00640 )
Butanoate metabolism (hsa00650 )
Metabolic pathways (hsa01100 )
GABAergic synapse (hsa04727 )
Reactome Pathway
Degradation of GABA (R-HSA-916853 )
BioCyc Pathway
MetaCyc:HS02477-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Divalproex sodium DM4RK0G Seizure disorder 8A6Z Approved [1]
L-Alanine DMZDN4W Dietary shortage 5B5K Approved [1]
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [1]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [1]
Vigabatrin DMYT0OG Alcohol dependence 6C40.2 Approved [2]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPP-115 DMK9NQI Tourette syndrome 8A05.00 Phase 2 [3]
K-828-AB DMJLNZQ Dementia 6D80-6D86 Phase 2 [4]
CPP -15 DMQCHU3 Infantile spasm 8A62.0 Phase 1 [3]
------------------------------------------------------------------------------------
2 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
4-hydroxybenzaldehyde DM471P5 Discovery agent N.A. Patented [5]
T83193 DMHO29Y Discovery agent N.A. Patented [6]
------------------------------------------------------------------------------------
11 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(4e)-4-Aminohex-4-Enoic Acid DMG27K1 Discovery agent N.A. Investigative [7]
1-(4-hydroxyphenyl)prop-2-en-1-one DM145QS Discovery agent N.A. Investigative [6]
3-chloro-1-(4-hydroxyphenyl)propan-1-one DM9OGNE Discovery agent N.A. Investigative [5]
4-Amino Hexanoic Acid DMYX34S Discovery agent N.A. Investigative [7]
4-hydroxy-3-nitrobenzaldehyde DMR0S8X Discovery agent N.A. Investigative [6]
4-hydroxybenzylamine DMJVPF0 Discovery agent N.A. Investigative [6]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [7]
Gamma-acetylenic GABA DMFSXOM Discovery agent N.A. Investigative [8]
NIPECOTIC ACID DMPV450 Discovery agent N.A. Investigative [9]
OXAMATE DMTYBC9 Discovery agent N.A. Investigative [9]
Sodium valproate DMX6PLV Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Glioma 2C82 Brainstem tissue 5.15E-01 0.74 0.76
Glioma 2C82 White matter 1.37E-01 0.59 0.46
------------------------------------------------------------------------------------

References

1 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 Clinical pipeline report, company report or official report of Catalyst Pharma.
4 Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
5 Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
6 Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology. 1981 Feb;31(2):207-11.
9 Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6.
10 Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Aviat Space Environ Med. 1978 Jul;49(7):877-9.